Diabetes, Obesity and Metabolism - Wiley Online Library
Diabetes, Obesity and Metabolism is the only interdisciplinary journal for high-quality research and reviews in the areas of diabetes, obesity and metabolism. We focus on clinical and experimental pharmacology and therapeutics in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems.
Diabetes, Obesity and Metabolism - 期刊影响因子 5.24 - JCR 1 区
《Diabetes, Obesity and Metabolism》主要是一份涵盖糖尿病、肥胖和新陈代谢相关领域的临床和实验药理学及治疗学的期刊。 该期刊优先考虑报告新疗法或现有疗法（包括饮食、运动和生活方式（非药物）干预）在人类或动物及细胞系统中对代谢和内分泌疾病的影响的 ...
Diabetes, Obesity and Metabolism: Vol 27, No 1
2024年12月5日 · Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.
DIABETES OBESITY & METABOLISM_影响因子(IF)_中科院分 …
3 天之前 · 《diabetes obesity & metabolism》期刊简介： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism.
Weight regain and cardiometabolic effects after withdrawal of ...
Materials and methods: STEP 1 (NCT03548935) randomized 1961 adults with a body mass index ≥ 30 kg/m 2 (or ≥ 27 kg/m 2 with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose escalation) or placebo, as an adjunct to lifestyle intervention. At week 68 ...
Diabetes, Obesity and Metabolism
2023年2月28日 · Division of Diabetes, Metabolism and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan Correspondence Toshihiko Yada, PhD, Center for Integrative Physiology, Kansai Electric Power Medical Research Institute, Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, 1-1, Yanagido ...
Diabetes, Obesity and Metabolism
2023年12月11日 · To assess whether oral semaglutide provides better glycaemic control, compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) continuation, in people with type 2 diabetes. Materials and Methods In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral ...
Diabetes, Obesity and Metabolism
2021年2月23日 · For metabolic disorders such as type 2 diabetes (T2D), weight loss can prevent T2D in individuals with prediabetes. It can improve and reverse T2D if weight loss is achieved early in the course of the disease.
Effects of once-weekly semaglutide on appetite, energy intake, …
Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5.
Comparative efficacy of glucose-lowering medications on body ... - PubMed
Semaglutide and SGLT-2 inhibitors conferred reductions both in body weight and blood pressure that were sustainable for over 1 year of treatment. These agents may be preferable treatment options for patients with type 2 diabetes who are overweight/obese and/or hypertensive.